Codexis, a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, has appointed Kathleen Sereda Glaub to its board of directors.
Glaub has spent 30 years with drug development and technology companies and will bring company-building and business strategy experience to the Codexis board.
She was recently appointed as CEO of Afferent Pharmaceuticals, a clinical-stage biotechnology company that is developing treatments for respiratory and urologic disorders and chronic pain. She has been a member of the company's board since 2013.
Prior to Afferent, Glaub was President of Plexxikon and co-led the company for 12 years from 2001 to 2013.
Before this, she was Chief Financial Officer of Cell Genesys, where she led the company’s financial strategy, and played a pivotal role in key acquisitions.